Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

In the second study, people either took Brukinsa or another BTK inhibitor for treating CLL/SLL called ibrutinib. The study looked at overall response, which is defined by how many people respond ...

Researchers sought to determine whether acalabrutinib plus venetoclax and obinutuzumab based on MRD assessment would yield deep remission in patients with R/R CLL.

Chronic lymphocytic leukemia (CLL), is a type of cancer that ... Calquence is also classified as a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that can cause cancer cells to grow.

The FDA has just approved its eleventh indication for BTK inhibitor Imbruvica (ibrutinib ... for newly-diagnosed patients aged 70 or below with CLL or another cancer – small lymphocytic ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...